Onconetix, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $815,371 | $2.5M | $5,963 | — | — |
| Gross profit | $632,913 | $1.1M | -$1.1M | — | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M |
| Operating expenses | $18.5M | $57.5M | $34.9M | $13.5M | $3.4M |
| Cost of revenue | $182,458 | $1.5M | $1.2M | — | — |
| Cash from operations | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Capital expenditure | — | $28,471 | $3,300 | $9,339 | $1,924 |
| Free cash flow | — | -$10.5M | -$13.6M | -$8.7M | -$2.0M |
| Share repurchases | — | $59,000 | — | $566,810 | — |
| Impairments | $11.5M | $3.5M | $14.7M | — | — |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M |
Shares outstanding 11.5M · Free float 49.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.